OncoMatch

OncoMatch/Clinical Trials/NCT05547529

The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer

Is NCT05547529 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for esophageal cancer.

Phase 3RecruitingBlokhin's Russian Cancer Research CenterNCT05547529Data as of Jun 2026Location: Russia

The purpose of this study is to evaluate the safety, feasibility and outcomes of neoadjuvant chemotherapy followed by esophagectomy versus neoadjuvant chemoradiotherapy followed by esophagectomy for locally advanced resectable esophageal squamous cell carcinoma cT3-4aN0M0, cT1-4aN1-3M0. This is non-inferiority study (neoadjuvant chemoradiotherapy has no advantage over neoadjuvant chemotherapy).

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Disease stage

Required: Stage CT1-4AN1-3M0 (AJCC/UICC 8th Edition)

Excluded: Stage CT4BCN0CM0

Clinical stage cT1-4aN1-3M0 (AJCC/UICC 8th Edition). Clinical stage cT4bcN0cM0 (AJCC/UICC 8th Edition) [excluded].

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 70

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

Cannot have received: radiotherapy

Cannot have received: targeted therapy

Lab requirements

Blood counts

white blood cells > 3.0 x 109/l; neutrophil > 2.0 × 109/l; hemoglobin > 90 g/l; platelets > 100 x 109/l

Kidney function

glomerular filtration rate (ccr) > 50 ml/min

Liver function

total bilirubin < 1.5 x uln; ast and alt < 3.0 x uln

Cardiac function

left ventricular ejection fraction > 50%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05547529 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage CT1-4AN1-3M0 is required.

Is there an age limit?

Yes. Patients must be 70 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify